GHSR-1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Americium-241 often enters landfills from discarded smoke detectors. The rules associated with the disposal of smoke detectors are relaxed in most jurisdictions. In the U.S., the "Radioactive Boy Scout" David Hahn was able to concentrate americium-241 from smoke detectors after managing to buy a hundred of them at remainder prices and also stealing a few. There have been a few cases of exposure to americium-241, the worst being Harold McCluskey who, at age 64, was exposed to 500 times the occupational standard for americium-241 as a result of an explosion in his lab. McCluskey died at age 75, not as a result of exposure, but of a heart disease which he had before the accident. Americium-241 has also been detected in the oceans as a result of nuclear testing conducted by various nations.
Troglitazone was developed by Daiichi Sankyo (Japan). In the United States, it was introduced and manufactured by Parke-Davis in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. The Food and Drug Administration (FDA) medical officer assigned to evaluate troglitazone, John Gueriguian, did not recommend its approval due to potentially high liver toxicity; Parke-Davis complained to the FDA, and Gueriguian was subsequently removed from his post. A panel of experts approved it in January 1997. Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the British market in December 1997, from the United States market in 2000, and from the Japanese market soon afterwards. It did not get approval in the rest of Europe. Troglitazone was developed as the first anti-diabetic drug having a mechanism of action involving a decrease in insulin resistance. At the time, it was widely believed that such drugs, by addressing the primary metabolic defect associated with Type 2 diabetes, would have numerous benefits including avoiding the risk of hypoglycemia associated with insulin and earlier oral antidiabetic drugs. It was further believed that reducing insulin resistance would potentially reduce the very high rate of cardiovascular disease that is associated with diabetes. Parke-Davis/Warner Lambert submitted the diabetes drug Rezulin for FDA review on July 31, 1996. The medical officer assigned to the review, Dr. John L.
On 10 September 2008, Matthew Bryza said before the Commission on Security and Cooperation in Europe, "But there's much more to the story than that. The conflict certainly did not begin on August 7th. [...] Already we saw that the Russian peacekeepers were playing a role in providing a shield, we believe, to the South Ossetians who were shooting at the Georgian positions." After the war, Irakli Okruashvili, who served as Minister of Defence of Georgia, claimed that he and President Saakashvili had prepared plans to retake South Ossetia and Abkhazia in 2005. The alleged original plans intended a two-pronged offensive into South Ossetia. Saakashvili believed that a Russian response would be checked by the United States through diplomacy, so he did not order the taking of the Roki Tunnel. Georgian forces raced to contain the Russian forces, but were "outmaneuvered by the Russians." Okruashvili said that Russian response would be "inevitable" as after 2006, Russians "repositioned and improved their military infrastructure in the North Caucasus, Abkhazia, and South Ossetia." The Georgian Army could have defended a few major towns from the Russians, but President Saakashvili "let the Russians in to avoid criticism and appear more of a victim". In September 2008, Matthew Bryza said there was no disagreement between the intercepted phone conversations (which were presented as evidence of Russian invasion on 7 August) and August 7 statements of Georgian officials made during the phone calls between Bryza and Georgians.
== History == The original Landspítali began operations on 20 December 1930. Ideas for a hospital that served the whole country was not new; in 1863, Jón Hjaltalín, the then Director of Health, proposed a bill that would establish such a hospital, but the bill was not voted on. During the period from 1863 to 1930, several hospitals operated in Reykjavík. The founding of Landspítali was the product of a long, hard struggle in which women were at the forefront and have ever since played a huge role in the country's hospital matters. In 2000, the Reykjavik City Hospital merged with Landspítali, and the new merged hospital was renamed as Landspítali University Hospital (Landspítali háskólasjúkrahús; LSH) until it reverted to its original name in 2007.
== Mechanism of action == Precise mechanism of antidepressant activity of SSRIs remains somewhat uncertain, but a number of biochemical functions associated with SSRI treatment have been established. SSRIs primarily inhibit SERT in the brain and have negligible effects on DAT and NET. The SSRIs also have less affinity for α1, α2, H1 and muscarinic receptors, which might explain the differences of adverse events between TCAs and SSRIs. Although SSRIs arrive rapidly to the brain after administration and the effects on 5-HT re-uptake can be measured instantly, it takes about 2–4 weeks to get therapeutic effects. The SSRIs have very high and selective affinity for SERT and after administration they inhibit SERT immediately. SERT inhibition is implicated in the antidepressant activity of SSRIs. 70-80% inhibition of SERT is usually necessary to induce antidepressant effects and higher dosage does not induce greater antidepressant effects for average patients. Higher dosage does, however, increase the incidence and severity of adverse events associated with excessive 5-HT re-uptake inhibition.
Sources: en.wikipedia.org
=== Legal status === The U.S. Food and Drug Administration (FDA) granted orphan drug designations in 2010 and 2020, and breakthrough therapy designation in 2016, on the basis of preliminary data from the phase II trial. In July 2020, and again in November 2020, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for emapalumab. In June 2025, the FDA approved emapalumab-lzsg for the treatment of macrophage activation syndrome (MAS) in patients with Still’s disease.
March 26 COVID-19 pandemic Maine reports its first case of the Lineage P.1 variant, which was originally detected in Brazil. Wisconsin confirms their first cases of the Lineage P.1 and 501.V2 variants of SARS-CoV-2. Arizona reports its first case of the 501.V2 variant, which was originally detected in South Africa. New Jersey amends its alcohol and cannabis laws to allow police to notify parents or guardians after a first-time offense by a minor, following strong opposition to the prohibition on first-time notifications implemented when New Jersey legalized cannabis the previous month. The U.S. Food and Drug Administration (FDA) approves Abecma to treat multiple myeloma. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. March 29 In Minnesota, opening statements begin at the trial of former police officer Derek Chauvin, who is accused of murdering 46-year-old black man George Floyd by kneeling on his neck. The Arkansas Senate passed, HB1570, a bill that prohibited normally functioning and physically healthy minors from puberty blockers, cross-sex hormones, and genital and non-genital invasive surgical alterations. A judge orders three men charged with plotting to kidnap Michigan Governor Gretchen Whitmer to stand trial, after a three-day preliminary hearing. Threat of terrorism charges are also dismissed against two of the defendants. Killing of Adam Toledo – A 13-year-old Latino boy, Adam Toledo, is shot and killed by an officer of the Chicago Police Department.
==== Seed-mediated growth ==== Seed-mediated growth is a synthetic method in which small, stable nuclei are grown in a separate chemical environment to a desired size and shape. Seed-mediated methods consist of two different stages: nucleation and growth. Variation of certain factors in the synthesis (e.g. ligand, nucleation time, reducing agent, etc.), can control the final size and shape of nanoparticles, making seed-mediated growth a popular synthetic approach to controlling morphology of nanoparticles. The nucleation stage of seed-mediated growth consists of the reduction of metal ions in a precursor to metal atoms. In order to control the size distribution of the seeds, the period of nucleation should be made short for monodispersity. The LaMer model illustrates this concept. Seeds typically consist small nanoparticles, stabilized by a ligand. Ligands are small, usually organic molecules that bind to the surface of particles, preventing seeds from further growth. Ligands are necessary as they increase the energy barrier of coagulation, preventing agglomeration. The balance between attractive and repulsive forces within colloidal solutions can be modeled by DLVO theory. Ligand binding affinity, and selectivity can be used to control shape and growth. For seed synthesis, a ligand with medium to low binding affinity should be chosen as to allow for exchange during growth phase. The growth of nanoseeds involves placing the seeds into a growth solution.
By the latter half of 1946, Korolev and rocket engineer Valentin Glushko had, with extensive input from German engineers, outlined a successor to the R-1, the R-2 with an extended frame and a new engine designed by Glushko, which entered service in November, 1951, with a range of 600 kilometres (370 mi), twice that of the R-1. This was followed in 1951 with the development of the R-5 Pobeda, the Soviet Union's first real strategic missile, with a range of 1,200 km (750 mi) and capable of carrying a 1 megaton (mt) thermonuclear warhead. The R-5 entered service in 1955. Scientific versions of the R-1, R-2 and R-5 undertook various experiments between 1949 and 1958, including flights with space dogs. Design work began in 1953 on the R-7 Semyorka with the requirement for a missile with a launch mass of 170 to 200 tons, range of 8,500 km and carrying a 3,000 kg (6,600 lb) nuclear warhead, powerful enough to launch a nuclear warhead against the United States. In late 1953 the warhead's mass was increased to 5.5 to 6 tons to accommodate the then planned theromonuclear bomb. The R-7 was designed in a two-stage configuration, with four boosters that would jettison when empty. On the 21 August 1957 the R-7 flew 6,000 km (3,700 mi), and became the worlds's first intercontinental ballistic missile. Two months later the R-7 launched Sputnik 1, the first artificial satellite, into orbit, and became the basis for the R-7 family which includes Sputnik, Luna, Molniya, Vostok, and Voskhod space launchers, as well as later Soyuz variants.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。